Agilon Health Inc (AGL) concluded trading on Wednesday at a closing price of $3.55, with 5.01 million shares of worth about $17.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -49.29% during that period and on January 22, 2025 the price saw a gain of about 4.11%. Currently the company’s common shares owned by public are about 411.96M shares, out of which, 303.29M shares are available for trading.
Stock saw a price change of 29.09% in past 5 days and over the past one month there was a price change of 82.05%. Year-to-date (YTD), AGL shares are showing a performance of 86.84% which decreased to -44.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.50 but also hit the highest price of $7.73 during that period. The average intraday trading volume for Agilon Health Inc shares is 4.26 million. The stock is currently trading 49.07% above its 20-day simple moving average (SMA20), while that difference is up 63.87% for SMA50 and it goes to -17.26% lower than SMA200.
Agilon Health Inc (NYSE: AGL) currently have 411.96M outstanding shares and institutions hold larger chunk of about 80.61% of that.
The stock has a current market capitalization of $1.46B and its 3Y-monthly beta is at 0.69. It has posted earnings per share of -$0.82 in the same period. It has Quick Ratio of 1.29 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGL, volatility over the week remained 10.46% while standing at 9.70% over the month.
Analysts are in expectations that Agilon Health Inc (AGL) stock would likely to be making an EPS of -0.13 in the current quarter, while forecast for next quarter EPS is 0.04 and it is -0.08 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.13 which is -0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.41 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -15.79% while it is estimated to increase by 38.08% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on January 10, 2025 offering a Neutral rating for the stock and assigned a target price range of between $1.75 and $2.25 to it. On December 16, 2024, Macquarie Initiated their recommendations, while on December 11, 2024, Bernstein Initiated their ratings for the stock with a price target of $2.50. Stock get a Mkt perform rating from JMP Securities on November 11, 2024.
